Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis

A Multicenter, Open Label, Randomized, Parallel-group Study to Evaluate the Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis With Inadequate Response to at Least One Disease Modifying Anti Rheumatic Drugs (DMARD)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00831922

Enrollment

Registered

2009-01-29

Start date

2004-09-30

Completion date

Unknown

Last updated

2018-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

Rheumatoid Arthritis, DMARD failure, ACR

Brief summary

The objective of this study is to evaluate the activity of 2 oral doses of AB1010 in subjects suffering from active RA who have shown an inadequate response to one DMARD including MTX or anti-TNF, after 3 months (12 weeks) of treatment. The safety and efficacy will be evaluated on: Rate of patients achieving ACR 20, 50, 70 and 90 DAS (disease activity score) after 3 months treatment ACRn after 3 months treatment Therapeutic maintenance of AB1010 at 3 months Quality of Life assessed by SF12 Health Assessment Questionnaire (HAQ) Clinical and biological safety Pharmacokinetic profile of AB1010

Interventions

DRUGmasitinib (AB1010)

3 mg/kg/day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Meet American College of Rheumatology (ACR) criteria for RA 2. Have active RA 3. ACR functional class I-III 4. Disease onset at \> 16 years of age 5. Disease duration of at least 6 months 6. Failure to one DMARD including methotrexate and anti-TNF alpha

Exclusion criteria

1. Pregnant or breastfeeding women 2. Inadequate bone marrow function 3. Current use of a DMARD within 4 weeks (or 5 half-lives, whichever is longer) of screening except for leflunomide which requires a specific wash-out 4. Any previous use of recombinant IL1-Ra 5. Current use of more than 1 non steroidal anti-inflammatory drug (NSAID) or change of dose of the NSAID within 4 weeks of baseline or NSAID use greater than the maximum recommended dose 6. Within 4 weeks before baseline, use of more than 10 mg/day of prednisone or equivalent or change in the dose of prednisone or equivalent, or having intra-articular corticosteroid injection or bolus intramuscular or intravenous treatment with corticosteroids (\>20 mg prednisone or equivalent

Design outcomes

Primary

Measure	Time frame
rate of patients achieving ACR 20, 50, 70 and 90 at 12 weeks	12 weeks

Secondary

Measure	Time frame
DAS (disease activity score) at 12 weeks	12 weeks
ACRn at 12 weeks	12 weeks
improvement of quality of life assessed by SF12 at 12 weeks	12 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026